The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Extended-release formulation of oxymorphone effective for pain relief in osteoarthritis

Newsletter